Abstract
The systemic administration of doxorubicin (DXR) decreases the number of epithelial cells and leukocytes in the small intestine of mice. Oral administration of muramyl tripeptide phosphatidylethanolamine (MTP-PE) prevented both disruption of intestinal architecture, and a decrease in the number of macrophages, and it induced the expression of IL-6, G-CSF, GM-CSF, and TNF-alpha in the intestinal tissue. The data suggest that the oral administration of MTP-PE can prevent chemotherapy-induced toxicity to the intestinal mucosa and hence infections due to translocation of aerobic bacteria from the intestine to the blood.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Acetylmuramyl-Alanyl-Isoglutamine / administration & dosage
-
Acetylmuramyl-Alanyl-Isoglutamine / analogs & derivatives*
-
Acetylmuramyl-Alanyl-Isoglutamine / pharmacology
-
Adjuvants, Immunologic / pharmacology*
-
Administration, Oral
-
Animals
-
Cytokines / genetics
-
Doxorubicin / toxicity
-
Female
-
Intestinal Mucosa / drug effects*
-
Intestinal Mucosa / pathology
-
Leukocytes / drug effects*
-
Mice
-
Mice, Inbred C57BL
-
Phosphatidylethanolamines / administration & dosage
-
Phosphatidylethanolamines / pharmacology*
-
RNA, Messenger / analysis
Substances
-
Adjuvants, Immunologic
-
Cytokines
-
Phosphatidylethanolamines
-
RNA, Messenger
-
mifamurtide
-
Acetylmuramyl-Alanyl-Isoglutamine
-
Doxorubicin